Oncocyte Corporation (OCX) financial statements (2022 and earlier)

Company profile

Business Address 15 CUSHING
IRVINE, CA 92618
State of Incorp. CA
Fiscal Year End December 31
SIC 2835 - In Vitro and In Vivo Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments36,5097,81822,4518,4628,36012,411
Cash and cash equivalents35,6057,14322,0728,0347,60010,174
Short-term investments9046753794287602,237
Receivables1,437203    
Prepaid expense24326480  182
Other current assets8529536  103
Other undisclosed current assets869646389180168 
Total current assets:39,1439,22622,9568,6428,52812,696
Noncurrent Assets
Finance lease, right-of-use asset2,779343 
Property, plant and equipment 4,4373,728614822688
Long-term investments and receivables 13,41710,964   
Long-term investments 13,41710,964   
Intangible assets, net (including goodwill)109,92924,196  746988
Goodwill18,6849,187    
Intangible assets, net (excluding goodwill)91,24515,009  746988
Prepaid expense 118268   
Deposits noncurrent assets    12075
Restricted cash and investments1,700     
Other noncurrent assets2648893   
Other undisclosed noncurrent assets5,7483,5941,850262  
Total noncurrent assets:120,42046,19316,9038761,6881,751
TOTAL ASSETS:159,56355,41939,8599,51810,21614,447
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:5,8233,9881,7561,4691,042797
Accounts payable2,447432469166175 
Accrued liabilities3,376   636549
Employee-related liabilities 3,5561,2871,303  
Other undisclosed accounts payable and accrued liabilities    231248
Debt1,3132,5411,1961,1851,138202
Due to related parties  62,1012,0992,703
Business combination, contingent consideration, liability1,388     
Other undisclosed current liabilities5,5962,4671,482806175573
Total current liabilities:14,1208,9964,4405,5614,4544,275
Noncurrent Liabilities
Long-term debt and lease obligation 1,7291,9635341,359310
Long-term debt, excluding current maturities 1,5081,9053471,070 
Finance lease, liability 22158
Capital lease obligations187289310
Liabilities, other than long-term debt76,6817,120    
Business combination, contingent consideration, liability76,6817,120    
Other undisclosed noncurrent liabilities3,5454,0912,618   
Total noncurrent liabilities:80,22612,9404,5815341,359310
Total liabilities:94,34621,9369,0216,0955,8134,585
Stockholders' equity
Stockholders' equity attributable to parent65,21733,48330,8383,4234,4039,862
Common stock252,954157,160124,58374,74259,96845,818
Accumulated other comprehensive income (loss)37   (888)(654)
Accumulated deficit(187,774)(123,677)(93,745)(71,319)(54,677)(35,302)
Total stockholders' equity:65,21733,48330,8383,4234,4039,862
TOTAL LIABILITIES AND EQUITY:159,56355,41939,8599,51810,21614,447

Income statement (P&L) ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Revenues7,7271,216 96  
Net investment income   96  
Cost of revenue(4,185)(1,855)    
Other undisclosed gross profit(3,354)     
Gross profit:188(639) 96  
Operating expenses(74,400)(33,082)(22,239)(15,202)(18,849)(11,140)
Other undisclosed operating income (loss) 4,010 (96)  
Operating loss:(74,212)(29,711)(22,239)(15,202)(18,849)(11,140)
Nonoperating income (expense)854(1,475)(187)(552)(526)(28)
Other nonoperating income (expense)(37)27(3)91  
Interest and debt expense1,141(102)(59)(77)  
Loss from continuing operations before equity method investments, income taxes:(72,217)(31,288)(22,485)(15,831)(19,375)(11,168)
Other undisclosed income (loss) from continuing operations before income taxes(1,141)102    
Loss from continuing operations before income taxes:(73,358)(31,186)(22,485)(15,831)(19,375)(11,168)
Income tax benefit9,2611,254    
Net loss:(64,097)(29,932)(22,485)(15,831)(19,375)(11,168)
Other undisclosed net income attributable to parent  5977  
Net loss available to common stockholders, diluted:(64,097)(29,932)(22,426)(15,754)(19,375)(11,168)

Comprehensive Income ($ in thousands)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Net loss:(64,097)(29,932)(22,485)(15,831)(19,375)(11,168)
Comprehensive loss:(64,097)(29,932)(22,485)(15,831)(19,375)(11,168)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent37 5977(234)(304)
Comprehensive loss, net of tax, attributable to parent:(64,060)(29,932)(22,426)(15,754)(19,609)(11,472)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: